智飞生物：关于带状疱疹mRNA疫苗临床试验申请获得受理的公告

Core Points - The company announced that its subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., has received the clinical trial application acceptance notice for its shingles mRNA vaccine from the National Medical Products Administration [2] Group 1 - The shingles mRNA vaccine is developed by the company's subsidiary, indicating a focus on innovative vaccine technology [2] - The acceptance notice allows the subsidiary to conduct clinical trials within 60 days if no negative or questioning opinions are received from the drug review center [2]